Literature DB >> 15153967

Smokeless tobacco cessation guidelines for health professionals in England.

R West1, A McNeill, M Raw.   

Abstract

Smokeless tobacco is used in the UK predominantly by members of the Indian, Pakistani and especially Bangladeshi communities. The most commonly used form is tobacco mixed with lime and additional psychoactive compounds, most notably areca nut. The resulting "quid" is chewed or held in the mouth. Studies from Asia indicate that use of this kind of product is linked with an increased risk of oral cancers and possibly low birth-weight infants. There is little high quality research evaluating interventions to promote cessation of smokeless tobacco use, especially of the forms used in the UK. However, what evidence there is suggests that advice to stop coupled with behavioural support and counselling may increase long-term abstinence rates by some 5-10%. It seems appropriate therefore to recommend that dentists, GPs and other relevant health professionals should routinely assess and record smokeless tobacco use in patients belonging to relatively high prevalence groups, that they ensure that smokeless tobacco users know the potential health risks (as well as the health risks of smoking) and that they advise them to stop and keep a record of the outcome. Dental professionals should also examine the oral cavity of smokeless tobacco users for lesions when the opportunity arises. Patients expressing an interest in stopping should be referred to specialist smoking cessation services for behavioural support and specialists in areas of high smokeless tobacco use will need to ensure that they are sufficiently knowledgeable and their services sufficiently accessible to these users. There is insufficient evidence to recommend the use of nicotine replacement therapy or bupropion to aid smokeless tobacco cessation. Research is needed in the UK to quantify the personal and population health risks from smokeless tobacco, the benefits of stopping, the effectiveness of interventions aimed at promoting cessation and patterns of use, knowledge and attitudes of users.

Entities:  

Mesh:

Year:  2004        PMID: 15153967     DOI: 10.1038/sj.bdj.4811286

Source DB:  PubMed          Journal:  Br Dent J        ISSN: 0007-0610            Impact factor:   1.626


  7 in total

1.  Levels of toxins in oral tobacco products in the UK.

Authors:  A McNeill; R Bedi; S Islam; M N Alkhatib; R West
Journal:  Tob Control       Date:  2006-02       Impact factor: 7.552

2.  Self-help materials for the prevention of smoking relapse: study protocol for a randomized controlled trial.

Authors:  Fujian Song; Richard Holland; Garry R Barton; Max Bachmann; Annie Blyth; Viv Maskrey; Paul Aveyard; Stephen Sutton; Jo Leonardi-Bee; Thomas H Brandon
Journal:  Trials       Date:  2012-05-30       Impact factor: 2.279

3.  Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.

Authors:  Melanie Y Bertram; Stephen S Lim; Angela L Wallace; Theo Vos
Journal:  Tob Control       Date:  2007-08       Impact factor: 7.552

Review 4.  Interventions for smokeless tobacco use cessation.

Authors:  Jon O Ebbert; Muhamad Y Elrashidi; Lindsay F Stead
Journal:  Cochrane Database Syst Rev       Date:  2015-10-26

5.  Guggulsterone targets smokeless tobacco induced PI3K/Akt pathway in head and neck cancer cells.

Authors:  Muzafar A Macha; Ajay Matta; Shyam Singh Chauhan; K W Michael Siu; Ranju Ralhan
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

6.  Socio-demographic correlates of betel, areca and smokeless tobacco use as a high risk behavior for head and neck cancers in a squatter settlement of Karachi, Pakistan.

Authors:  Samia Mazahir; Rabia Malik; Maria Maqsood; Kanwal Aliraza Merchant; Farida Malik; Atif Majeed; Zafar Fatmi; Muhammad Rizwanulhaq Khawaja; Shehzad Ghaffar
Journal:  Subst Abuse Treat Prev Policy       Date:  2006-04-26

Review 7.  The Reasons for Using Smokeless Tobacco: A Review.

Authors:  Mahnaz Solhi; Esmaeil Fattahi; Zahra Sadat Manzari; Prakash C Gupta; Mehdi Kargar; Parisa Kasmaei; Hadis Barati
Journal:  Iran J Public Health       Date:  2021-03       Impact factor: 1.429

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.